| 09/09/2026 5:00 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/31/2026 8:11 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/24/2026 9:49 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/18/2026 5:00 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/10/2026 9:42 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/10/2026 9:47 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/04/2026 4:23 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/04/2026 12:40 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 08/04/2026 9:39 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/31/2026 7:54 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/21/2026 5:01 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Get the Latest News and Ratings for NVO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Novo Nordisk A/S and its competitors with MarketBeat's FREE daily newsletter.
|
| 07/13/2026 8:24 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 07/06/2026 6:00 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/29/2026 3:16 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/24/2026 5:00 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/22/2026 7:00 AM | Innate Pharma SA (1598599) Subject Innate Pharma SA (1598599) Subject Novo Nordisk A/S (353278) Filed by | Form SCHEDULE 13G/A | |
| 06/15/2026 6:42 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/08/2026 8:49 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 06/01/2026 6:53 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/27/2026 5:00 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/22/2026 1:32 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/22/2026 11:29 AM | Novo Nordisk A/S (353278) Filer | Form SD Specialized Disclosure Report | |
| 05/22/2026 9:01 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/18/2026 9:29 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/13/2026 6:53 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/06/2026 6:51 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 05/05/2026 8:30 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/27/2026 6:21 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 8:38 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/20/2026 5:50 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/13/2026 6:52 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 04/10/2026 7:30 AM | Innate Pharma SA (1598599) Subject Innate Pharma SA (1598599) Subject Novo Nordisk A/S (353278) Filed by | Form SCHEDULE 13G/A | |
| 04/07/2026 6:28 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/30/2026 8:05 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/27/2026 6:47 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/27/2026 5:33 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/26/2026 12:02 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/23/2026 7:56 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/20/2026 7:11 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/17/2026 6:10 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/09/2026 6:53 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
Why major institutions are piling into this digital asset now (Ad) BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid.
The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned. Get the name, the ticker, and exactly how to buy it |
| 03/02/2026 10:47 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 03/02/2026 6:57 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/23/2026 7:19 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/23/2026 5:28 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/20/2026 6:45 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/17/2026 5:10 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/10/2026 5:16 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/09/2026 7:32 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/05/2026 1:54 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/05/2026 1:55 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/04/2026 8:28 AM | Novo Nordisk A/S (353278) Filer | Form IRANNOTICE | |
| 02/04/2026 8:23 AM | Novo Nordisk A/S (353278) Filer | Form 20-F Registration statement / Annual report / Transition report | |
| 02/04/2026 7:43 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/03/2026 11:29 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/03/2026 11:47 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 11:43 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 02/02/2026 5:05 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 12/23/2025 8:56 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/25/2025 7:19 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/24/2025 6:23 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/17/2025 2:35 PM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/14/2025 9:12 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/14/2025 5:00 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/12/2025 5:10 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/07/2025 5:00 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 11/05/2025 8:28 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/30/2025 6:38 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/21/2025 8:15 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/21/2025 8:16 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 10/21/2025 7:00 AM | Innate Pharma SA (1598599) Subject Innate Pharma SA (1598599) Subject Novo Nordisk A/S (353278) Filed by | Form SCHEDULE 13G/A | |
| 10/09/2025 6:37 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
| 09/10/2025 5:05 AM | Novo Nordisk A/S (353278) Filer | Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |